Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 +/- BCG or Adebrelimab in NMIBC
NCT05410730Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-1501 in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum tolerated dose at 2 years and 3 more. Started Nov 2022; status: recruiting.
02
Drugs
SHR-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05410730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410730.